Most DDR inhibitors operate on the principle of synthetic lethality, whereby inhibiting a DDR pathway is fetal to cells already deficient in a complementary DNA repair mechanism (e.g., PARP inhibitors in BRCA-mutated cancers) (Yang et al., 2012). The gene discussed is PARP1; the disease is cancer.